These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24738462)

  • 1. [Urinary prostaglandins E2 correlates to overactive bladder symptoms in patients with benign prostatic hyperplasia].
    Zhang YJ; Bai Q
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):244-8. PubMed ID: 24738462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
    Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
    Liu HT; Kuo HC
    Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
    Tsujimura A; Takao T; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Kiuchi H; Hirai T; Tsujimoto Y; Miura H; Kanno N; Higashino M; Nakamura Y; Nishimura K; Nonomura N
    Urology; 2011 Nov; 78(5):1058-62. PubMed ID: 21908025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
    Matsukawa Y; Takai S; Asai K; Kasugai S; Narita H; Komatsu T; Kashiwagi Y; Kato M; Yamamoto T; Gotoh M
    Urology; 2015 Sep; 86(3):558-64. PubMed ID: 26189139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
    Kim SR; Moon YJ; Kim SK; Bai SW
    Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
    Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
    Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Wang LW; Li JL; Yu Y; Xiao RH; Huang HW; Kuang RR; Hai B
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):531-535. PubMed ID: 28786061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of brainderived neurotrophic factor in urine of patients with benign prostatic hyperplasia complicated overactive bladder symptoms].
    Hu H; Xu KX; Zhang XP; Fang ZW; Chen JW; Huo F; Wang D; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):519-23. PubMed ID: 25131461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
    Liu HT; Kuo HC
    Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
    Matsukawa Y; Majima T; Takai S; Funahashi Y; Kato M; Gotoh M
    Urol Int; 2019; 103(4):439-443. PubMed ID: 31554005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.